Broward Health Medical Center Becomes First Hospital in Florida to Adopt Advanced Genesis Robotic Technology to Treat Heart Rhythm Disorders

ST. LOUIS, April 07, 2021 (GLOBE NEWSWIRE) -- (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that Broward Health Medical Center is establishing a robotic electrophysiology program to expand access to advanced minimally-invasive treatment of heart rhythm disorders in Florida. Broward Health Medical Center will be the only hospital in South Florida offering robotic technology to treat patients suffering from arrhythmias and is the first in Florida, and among the first in the nation, to adopt the latest Genesis Robotic Magnetic Navigation system.

“The adoption of this advanced robotic technology further reinforces the commitment Broward Health Medical Center has toward providing high quality cardiac care for patients suffering from all types of arrhythmias,” said Ahmed Osman, M.D., Medical Director of the Cardiac Electrophysiology Lab. “This technology helps enhance the reach, precision and stability of the traditional tools used in ablation therapy, while having inherent attributes that can increase safety. We are very excited to have access to this technology for our patients.”

Robotic Magnetic Navigation introduces the benefits of robotic precision and safety to cardiac ablation, a common, minimally invasive procedure to treat arrhythmias. Tens of millions of individuals worldwide suffer from arrhythmias – abnormal heart rhythms that result when the heart beats too quickly, too slowly, or with an irregular pattern. When left untreated, arrhythmias may significantly increase the risk of stroke, heart failure, and sudden cardiac arrest.

“On the heels of Broward Health Medical Center’s recent IAC accreditation for electrophysiology, we are excited to bring this latest technology to our complex arrhythmia program,” said Heather Havericak, CEO of Broward Health Medical Center. “Studies suggest that one in four Americans over the age of 40 could develop irregular heartbeats, and over 2.3 million Americans suffer from atrial fibrillation. The adoption of Robotic Magnetic Navigation supports our commitment to providing comprehensive cardiac care for our community and the greater tri-county area.”

“We are delighted to partner with Broward Health to help enhance quality of care and access to therapy for patients in Florida,” said David Fischel, Chairman and CEO of Stereotaxis. “We applaud their leadership and look forward to supporting their efforts to build a preeminent heart rhythm program in the region.”

About Stereotaxis

is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit .

This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to continue to manage expenses and cash burn rate at sustainable levels, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from healthcare policy in the United States, including changes in government reimbursement of procedures, dependence upon third-party vendors, timing of regulatory approvals, the impact of the recent coronavirus (COVID-19) pandemic and our response to it, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.